Shathiyah Kulandavelu

Shathiyah Kulandavelu

Auto-generated profile, based on publicly available information

Shathiyah Kulandavelu

University of Miami Miller School of Medicine

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Stem Cells Translational Medicine
Verified
Journal Article
Open access
PDF file
MSMayank Sharma
Mayank Sharma
MBMichael A Bellio
Michael A Bellio
MBMerline Benny
Merline Benny
SKShathiyah Kulandavelu
Shathiyah Kulandavelu
PCPingping Chen
Pingping Chen
KYKaren Young
Karen Young
Mesenchymal stem cell (MSC) extracellular vesicles (EVs) have beneficial effects in preclinical bronchopulmonary dysplasia and pulmonary hypertension (BPD-PH) models. The optimal source, dosing, route, and duration of effects are however unknown. The objectives of this study were to (a) compare the efficacy of GMP-grade EVs obtained from Wharton’s Jelly MSCs (WJ-MSCs) and bone marrow (BM-MSCs), (b) determine the optimal dosing and route of administration, (c) evaluate its long-term effects, and (d) determine how MSC EVs alter the lung transcriptome. Newborn rats exposed to normoxia or hyperoxia (85% O2) from postnatal day (P)1-P14 were given (a) intra-tracheal (IT) BM or WJ-MSC EVs or placebo, (b) varying doses of IT WJ-MSC EVs, or (c) IT or intravenous (IV) WJ-MSC EVs on P3. Rats were evaluated at P14 or 3 months. Early administration of IT BM-MSC or WJ-MSC EVs had similar beneficial effects on lung structure and PH in hyperoxia-exposed rats. WJ-MSC EVs however had superior effects on cardiac remodeling. Low, medium, and high dose WJ-MSC EVs had similar cardiopulmonary regenerative effects. IT and IV WJ-MSC EVs similarly improved vascular density and reduced PH in hyperoxic rats. Gene-set enrichment analysis of transcripts differentially expressed in WJ-MSC EV-treated rats showed that induced transcripts were associated with angiogenesis. Long-term studies demonstrated that a single early MSC EV dose has pulmonary vascular protective effects 3 months after administration. Together, our findings have significant translational implications as it provides critical insight into the optimal source, dosing, route, mechanisms of action, and duration of effects of MSC-EVs for BPD-PH.

15 June 2022 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
RDRaul Dulce
Raul Dulce
RKRosemeire M Kanashiro-Takeuchi
Rosemeire M Kanashiro-Takeuchi
LTLauro M Takeuchi
Lauro M Takeuchi
Alessandro SalernoAlessandro Salerno
Alessandro Salerno
Amarylis Claudine WanschelAmarylis Claudine Wanschel
Amarylis Claudine Wanschel
JHJoshua M. Hare
Joshua M. Hare
To test the hypothesis that the activation of the growth hormone-releasing hormone (GHRH) receptor signalling pathway within the myocardium both prevents and reverses diastolic dysfunction and pathophysiologic features consistent with heart failure with preserved ejection fraction (HFpEF). Impaired myocardial relaxation, fibrosis, and ventricular stiffness, among other multi-organ morbidities, characterize the phenotype underlying the HFpEF syndrome. Despite the rapidly increasing prevalence of HFpEF, few effective therapies have emerged. Synthetic agonists of the GHRH receptors reduce myocardial fibrosis, cardiomyocyte hypertrophy, and improve performance in animal models of ischaemic cardiomyopathy, independently of the growth hormone axis. CD1 mice received 4- or 8-week continuous infusion of angiotensin-II (Ang-II) to generate a phenotype with several features consistent with HFpEF. Mice were administered either vehicle or a potent synthetic agonist of GHRH, MR-356 for 4-weeks beginning concurrently or 4-weeks following the initiation of Ang-II infusion. Ang-II-treated animals exhibited diastolic dysfunction, ventricular hypertrophy, interstitial fibrosis, and normal ejection fraction. Cardiomyocytes isolated from these animals exhibited incomplete relaxation, depressed contractile responses, altered myofibrillar protein phosphorylation, and disturbed calcium handling mechanisms (ex vivo). MR-356 both prevented and reversed the development of the pathological phenotype in vivo and ex vivo. Activation of the GHRH receptors increased cAMP and cGMP in cardiomyocytes isolated from control animals but only cAMP in cardiac fibroblasts, suggesting that GHRH-A exert differential effects on cardiomyocytes and fibroblasts. These findings indicate that the GHRH receptor signalling pathway(s) represents a new molecular target to counteract dysfunctional cardiomyocyte relaxation by targeting myofilament phosphorylation and fibrosis. Accordingly, activation of GHRH receptors with potent, synthetic GHRH agonists may provide a novel therapeutic approach to management of the myocardial alterations associated with the HFpEF syndrome. Proposed mechanism of action for GHRH-As to modulate the Excitation-Contraction Coupling (ECC). It is well known that activation of GHRHRs (GPCR) induces the adenylyl cyclase (AC)/cyclic AMP/protein kinase A (PKA) pathway. PKA can both phosphorylate sarcomeric and calcium handling proteins and activate soluble guanylyl cyclase (sGC). This pathway also promotes reparative mechanisms at transcriptional level. On the other hand, has been well demonstrated that GHRH-As also promote activation of AKT (PKB) among other kinases. Endothelial Nitric Oxide Synthase eNOS) is also activated by GHRH. The generated nitric oxide (NO) in turn activates sGC to produce the second messenger cGMP, an activator of the protein kinase G (PKG). This kinase is also able to phosphorylate the above-mentioned proteins. This pathway has been proposed to be activated downstream GHRHRs through activation of PI3K by the Gβγ proteins or β-arrestins (among other possible mechanisms).

1 March 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SKShathiyah Kulandavelu
Shathiyah Kulandavelu
RDRaul Dulce
Raul Dulce
CMChristopher I. Murray
Christopher I. Murray
MBMichael A. Bellio
Michael A. Bellio
JFJulia Fritsch
Julia Fritsch
JHJoshua M. Hare
Joshua M. Hare
Background: Preeclampsia, a leading cause of maternal and fetal mortality and morbidity, is characterized by an increase in S‐nitrosylated proteins and reactive oxygen species, suggesting a pathophysiologic role for dysregulation in nitrosylation and nitrosative stress. Methods and Results: Here, we show that mice lacking S‐nitrosoglutathione reductase ( GSNOR −⁄− ), a denitrosylase regulating protein S‐nitrosylation, exhibit a preeclampsia phenotype, including hypertension, proteinuria, renal pathology, cardiac concentric hypertrophy, decreased placental vascularization, and fetal growth retardation. Reactive oxygen species, NO, and peroxynitrite levels are elevated. Importantly, mass spectrometry reveals elevated placental S‐nitrosylated amino acid residues in GSNOR −⁄− mice. Ascorbate reverses the phenotype except for fetal weight, reduces the difference in the S‐nitrosoproteome, and identifies a unique set of S‐nitrosylated proteins in GSNOR −⁄− mice. Importantly, human preeclamptic placentas exhibit decreased GSNOR activity and increased nitrosative stress. Conclusions: Therefore, deficiency of GSNOR creates dysregulation of placental S‐nitrosylation and preeclampsia in mice, which can be rescued by ascorbate. Coupled with similar findings in human placentas, these findings offer valuable insights and therapeutic implications for preeclampsia.

1 February 2024 in Hypertension
Verified
Journal Article
Open access
OQOdayme Quesada
Odayme Quesada
SKShathiyah Kulandavelu
Shathiyah Kulandavelu
CVCatherine J. Vladutiu
Catherine J. Vladutiu
EDEmily DeFranco
Emily DeFranco
MMMargo B. Minissian
Margo B. Minissian
SCSusan Cheng
Susan Cheng
BACKGROUND: Hypertensive disorders of pregnancy (HDP) are associated with long-term maternal risks for cardiovascular disease for reasons that remain incompletely understood. METHODS: The HCHS/SOL (Hispanic Community Health Study/Study of Latinos), a multi-center community-based cohort of Hispanic/Latino adults recruited 2008 to 2011, was used to evaluate the associations of history of de novo HDP (gestational hypertension, preeclampsia, eclampsia) with echocardiographic measures of cardiac structure and function in Hispanic/Latina women with ≥1 prior pregnancy and the proportion of association mediated by current hypertension (>140/90 mm Hg or antihypertensive therapy). RESULTS.: The study cohort included 5168 Hispanic/Latina women with an average age (SD) of 58.7 (9.7) years at time of echocardiogram. Prior de novo HDP was reported by 724 (14%) of the women studied and was associated with lower left ventricle (LV) ejection fraction −0.66 (95% confidence interval [CI], −1.21 to −0.11), higher LV relative wall thickness 0.09 (95% CI, 0–0.18), and 1.39 (95% CI, 1.02–1.89) higher risk of abnormal LV geometry after adjusting for blood pressure and other confounders. The proportion of the association mediated by current hypertension between HDP and LV ejection fraction was 0.09 (95% CI, 0.03–0.45), LV relative wall thickness was 0.28 (95% CI, 0.16–0.51), abnormal LV geometry was 0.14 (95% CI, 0.12–0.48), concentric left ventricular hypertrophy was 0.31 (95% CI, 0.19–0.86), and abnormal LV diastolic dysfunction was 0.58 (95% CI, 0.26–0.79). CONCLUSIONS.: In a large cohort of Hispanic/Latina women those with history of de novo HDP had detectable and measurable subclinical alterations in cardiac structure and both systolic and diastolic dysfunction that were only partially mediated by current hypertension.

1 August 2020 in F&S Science
Verified
Journal Article
Closed access
KCKevin Y. Chu
Kevin Y. Chu
SKShathiyah Kulandavelu
Shathiyah Kulandavelu
TMThomas A. Masterson
Thomas A. Masterson
Emad IbrahimEmad Ibrahim
Emad Ibrahim
HAHimanshu Arora
Himanshu Arora
Ranjith RamasamyRanjith Ramasamy
Ranjith Ramasamy

7 July 2022 in Reproductive Sciences
Verified
Journal Article
Closed access
PDF file
ELEun Lee
Eun Lee
SKShathiyah Kulandavelu
Shathiyah Kulandavelu
NGNardhy Gomez-Lopez
Nardhy Gomez-Lopez
EBElizabeth A. Bonney
Elizabeth A. Bonney